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Abstract: Tissue engineering has gained attention as an alternative approach for developing small
diameter tissue-engineered vascular grafts intended for bypass surgery, as an option to treat coronary
heart disease. To promote the formation of a healthy endothelial cell monolayer in the lumen of the
graft, polycaprolactone/gelatin/fibrinogen scaffolds were developed, and the surface was modified
using thermoforming and coating with collagen IV and fibronectin. Human cord blood-derived
endothelial cells (hCB-ECs) were seeded onto the scaffolds and the important characteristics of a
healthy endothelial cell layer were evaluated under static conditions using human umbilical vein
endothelial cells as a control. We found that polycaprolactone/gelatin/fibrinogen scaffolds that
were thermoformed and coated are the most suitable for endothelial cell growth. hCB-ECs can
proliferate, produce endothelial nitric oxide synthase, respond to interleukin 1 beta, and reduce
platelet deposition.
Keywords: Vascular tissue engineering; umbilical cord blood; human cord blood-derived endothelial
cells; endothelialization; vascular graft
1. Introduction
Coronary heart disease (CHD) resulting from atherosclerosis remains the leading cause of death
in the United States [1]. CHD alone caused approximately 1 of 7 deaths in 2013, and 660,000
hospitalizations as a result of myocardial infarctions [2]. Once a coronary artery is compromised,
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a vascular bypass is an option to restore blood flow to tissues distal of the restriction or blockage [3].
Artery bypass graft surgery procedures usually involve the replacement of a coronary artery with
an autologous vessel such as the saphenous vein or internal mammary artery [4,5]. Nevertheless,
autologous grafts are not always available due to preexisting vascular conditions, or their use in a
prior bypass operation [6]. The commercial alternatives to autologous grafts are vessels made of
synthetic materials such as polytetrafluoroethylene (PTFE) or polyethylene terephthalate (known as
Dacron). These grafts have been implemented with some success in medium and large diameter vessel
replacement, but their efficacy is limited when used in small diameter vessels (<6 mm) where low
blood flow makes the synthetic graft difficult to cellularize and more prone to thrombus formation,
calcification, and intimal hyperplasia [3,6,7]. Therefore, there is an urgent need for small diameter
graft alternatives that are able to support cell growth and match the mechanical properties of a native
coronary artery while reducing the risk of acute thrombus formation and restenosis [8,9].
Recently, tissue engineering has gained attention as an alternative approach for developing small
diameter vascular grafts from biocompatible natural or synthetic polymers [10,11]. Different methods
have been used to fabricate tissue-engineered vascular grafts (TEVGs), such as solvent casting, phase
separation, and electrospinning [10]. Electrospinning, in particular, has been extensively utilized
to create fibrous scaffolds produced from nonwoven meshes containing fibers with diameters from
micrometers to nanometers [10,12–14]. Its ability to combine the mechanical durability of synthetic
materials with the cell compatibility of natural polymers makes electrospinning particularly attractive
for TEVGs [10]. Some studies have reported the application of polycaprolactone scaffolds for the
fabrication of TEVGs [15–17]. Previously we found that the incorporation of both gelatin and fibrinogen
enhances the compliance which is critical for a functional vascular graft [18]. To further enhance the
biocompatibility of a scaffold, surface modification has been shown to promote cell attachment,
viability, and biological response of cells in the biomaterial. One of the common surface modification
techniques is extracellular matrix protein coating [11].
For a TEVG to be successful, it needs to promote the formation of a healthy endothelial cell
monolayer in the lumen of the graft [19]. Endothelial cells play a critical role in the control of
vascular function. They participate in all aspects of vascular homeostasis, but they are also critical
in physiological or pathological processes like regulation of vascular tone, inflammation, and in the
prevention of thrombosis and intimal hyperplasia [20–22]. Therefore, an establishment of a healthy
endothelium is crucial for the long-term success of a TEVG [19]. Endothelial progenitor cells as a
source of cells for TEVG may be obtained from many sources including bone marrow, peripheral
blood, and cord blood. Cord blood is an ideal source, since it has not been exposed to exogenous
conditions that could diminish its numbers or function, such as diabetes, autoimmune disease, or old
age [23]. In recent years, human umbilical cord blood-derived endothelial cells (hCB-ECs) have been
increasingly used for tissue engineering applications, due to the highly proliferative capacity of these
stem and differentiated cells in vitro [24]. An increased rate of proliferation results in less time and
costs involved when “seeding” the grafts. A variety of studies have shown that hCB-ECs develop
into a homogeneous population of endothelial cells that can be passaged 50–100 times before reaching
senescence or losing the differentiated endothelial cell phenotype [24–26] as compared to other sources
of endothelial precursor cells (such as adult peripheral blood), owing in part to the “young” age of
the CB cells, which again decreases overall cost. In addition, a younger source of stem cells and EC
derived from those stem cells is advantageous with respect to potential negative epigenetic effects
observed in adult sources of cells. Studies comparing the protein profile of hCB-ECs with human
umbilical vein endothelial cells (HUVECs) concluded that hCB-ECs display a higher proliferative
capacity, higher sensitivity to angiogenic factors, and a differentiated production of the antioxidant
enzyme manganese superoxide dismutase, which makes hCB-ECs more tolerant to oxidative stress
than HUVECs [24,27–32] and more likely to survive in vivo.
In this study, gelatin/fibrinogen/polycaprolactone scaffolds were electrospun and
surface-modified through a thermoforming process and coated with a blend of collagen IV
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and fibronectin. hCB-ECs were tested for their ability to proliferate and remain on the surface
of the scaffold in formation of a monolayer. We also assessed whether the attached cells could
function similar to a mature endothelial cell layer quantifying their response to pro-inflammatory
cytokine interleukin 1 beta (IL-1β), the production of endothelial nitric oxide synthase (eNOS), and
antithrombotic capacities as compared to HUVECs. This study evaluates the suitability of a surface
modified biomaterial for endothelialization of a vascular graft as well as the use of hCB-ECs as a cell
source for cardiovascular tissue engineering applications.
2. Materials and Methods
2.1. Cell Isolation and Cell Characterization
Human umbilical vein endothelial cells (HUVECs) (ATCC, Manassas, VA, USA) were purchased
and cultured per manufacturer’s instructions as a positive control. Human cord blood-derived
endothelial cells (hCB-ECs) were isolated as follows and de-identified umbilical cord blood
(n = 3 donors) was obtained from the University of Arizona Biorepository per protocols approved
by the University of Arizona’s Institutional Review Board (IRB). After collection, the isolation
and differentiation procedures followed those described by Javed et al. (2008) [33], with minor
modifications. Briefly, cord blood (20–100 mL) was diluted 1:1 with Hank’s balanced salt solution
(HBSS), and then overlaid onto an equivalent volume of Histopaque 1077 (Sigma-Aldrich, St. Louis,
MO, USA). To isolate mononuclear cells, the diluted cord blood was centrifuged for 30 min at room
temperature at 740× g. The isolated mononuclear cells were washed and resuspended in 12 mL
complete EGM-2 plus medium (Lonza, Basel, Switzerland), supplemented with 15% fetal bovine
serum (Thermo Fisher Scientific, Pittsburgh, PA, USA). The cells were seeded onto 3 wells of a 6-well
plate precoated with rat tail collagen type I (Life Technologies, Carlsbad, CA, USA) and maintained in
a humidified environment at 37 ◦C and 5% CO2. The medium was changed daily for the first 7 days
and every other day until the first passage. Colonies of endothelial cells appeared between 5 and 22
days of culture.
Cell identity was confirmed by flow cytometry and immunocytochemistry (ICC) as previously
described [31] using mouse anti-human primary antibodies (BD Biosciences, Franklin Lakes, NJ, USA).
For flow cytometry, fluorescein isothiocyanate (FITC)-conjugated CD31 antibodies, allophycocyanin
(APC)-conjugated CD105 antibodies, and phycoerythrin (PE)-conjugated CD45 antibodies were used.
Fluorescence intensity per cell produced by the bound antibodies was measured and cells were counted
using the LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). For each flow cytometry
experiment, 10,000–30,000 cells were gated from a population of 500,000 cells. For ICC, cells were
cultured on glass coverslips coated with rat tail collagen I and the immunostaining was performed
using the FITC conjugated CD31 antibodies. Cell nuclei were counterstained using VECTSHIELD®
4′,6-diamidino-2-phenylindole (DAPI)-containing mounting media (Vector Laboratories, Burlingame,
CA, USA). For all experiments performed, cells from passage 2–6 were used. Detailed information on
the antibodies used is provided in Table S1.
2.2. Scaffold Fabrication
Flat sheet scaffolds were fabricated by electrospinning. Briefly, polycaprolactone, (PCL,
80,000 MW; Sigma-Aldrich, St. Louis, MO, USA), gelatin extracted from porcine skin (Sigma-Aldrich,
St. Louis, MO, USA), and fraction I bovine fibrinogen (Sigma-Aldrich, St. Louis, MO, USA) were mixed
at a ratio of 50% PCL:40% gelatin:10% fibrinogen w/w (hereafter PCL-GF) [18,34,35]. The polymeric
blend was dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol (Sigma-Aldrich, St. Louis, MO, USA) to create
a 10% w/v solution under constant stirring until completely homogeneous. The solution was loaded
into a 5 mL BD syringe with a 23-gauge stainless steel dispensing blunt tip needle attached (CML
Supply, Lexington, KY, USA). The syringe was then loaded into a NE-1000 single syringe pump (New
Era Pump Systems Inc, Farmingdale, NY, USA) set to a pump rate of 30 µL/min. The distance from
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the needle tip to the target was 8 cm. The polymeric solution was electrospun with an applied voltage
of 15 kV, onto glass coverslips attached to a metallic target to create fine fibers. The resulting flat sheets
were cross-linked in 25% glutaraldehyde (Sigma-Aldrich, St. Louis, MO, USA) in vapor phase for 24 h.
The glutaraldehyde was evaporated in a convection oven overnight at 42 ◦C, which is a temperature
below the denaturation point of gelatin and fibrinogen [36,37]. Additionally, the scaffolds were rinsed
with deionized water to remove any cross-linker residues and uncross-linked gelatin [35]. This method
of removing glutaraldehyde was previously demonstrated no cytotoxicity of the cross-linked scaffolds
for the proliferation of smooth muscle cells [35].
2.3. Surface Modification
After cross-linking, the scaffolds were thermoformed by a technique previously reported by our
group [38]. The scaffolds were immersed in a water bath at 45 ◦C for 2 min, and then quickly placed
in between two glass slides. A pressure of approximately 45 mmHg was applied using a 25 mm
wide binder clip while the scaffolds were immersed once more in the 45 ◦C water bath for 5 min [39].
The scaffolds were equilibrated at room temperature for 10 min before the pressure was released.
Thermoformed scaffolds were sterilized with 70% ethanol for 1 h, rinsed with sterile 1× PBS and
then placed under UV light (254 nm) for 1 h. The sterile scaffolds were coated with a solution 1:1 of
collagen IV (Sigma-Aldrich, St. Louis, MO, USA) and fibronectin (Sigma-Aldrich, St. Louis, MO, USA)
in HBSS with a final concentration of 5 µg/mL for 24 h at 4 ◦C. This coating blend has previously
shown to promote hCB-EC growth when compared to Collagen IV alone (Figure S1). The coating
solution was carefully rinsed with sterile 1× PBS. The scaffolds were then designated as thermoformed
and coated (hereafter TC). The combined surface modification with thermoforming and coating was
selected because our preliminary data showed that scaffolds thermoformed and coated are most
favorable for cell attachment and spreading when compared to thermoformed alone or coated alone
(Figure S2).
2.4. Scaffold Imaging
PCL-GF scaffolds, both nontreated (hereafter NT) and thermoformed, were imaged using atomic
force microscopy (AFM). All AFM data was collected with a Cypher (Asylum Research and Oxford
Instruments company, Santa Barbara, CA, USA) using AC Topography mode in air and NSC15 tapping
mode probes (Mikromasch, Watsonville, CA, USA). For each scaffold treatment, 3 samples were imaged
in 4 random areas of 25 µm2 along the mesh of fibers, and roughness values (Ra) were calculated after
applying a first order flatten on all surfaces using Asylum Research software version 14.13.134.
Scanning electron microscopy (SEM) was performed on both TC and NT scaffolds. Briefly,
samples were mounted onto aluminum stubs, grounded with silver paint, and sputter-coated with
6 nm gold/palladium (Cressington Sputter-coater Auto 108, Cressington, Watford, UK). En face
views of the samples (n = 6 scaffolds each) were imaged using a JEOL JSM-6335F scanning electron
microscope (JEOL USA, Peabody, MA, USA) at 3 kV at a magnification of 10,000×. The SEM images
were binarized and the porosity was calculated as the ratio of the total number of fiber pixels to the
total number of pixels in the image. The fiber diameter was calculated by manually measuring the
diameter of 120 randomly selected fibers per scaffold treatment via freehand lines superimposed over
the SEM images in ImageJ.
Multiphoton microscopy was used for the three-dimensional imaging of our electrospun scaffolds.
The Pitt Advanced Intravital Microscope (AIM) for multiphoton imaging at the University of
Pittsburgh Soft Tissue Biomechanics Laboratory allowed us to measure the change in scaffold thickness.
This Olympus BX51 upright laser scanning microscope (Olympus, Tokyo, Japan) was coupled to a
120-fs tunable pulsed Titanium-Sapphire laser (Coherent Inc, Santa Clara, CA, USA) and an Olympus
XLUMPLFL 20× water immersion objective with a numerical aperture of 0.9 [40,41]. The fibers were
imaged centering the laser at 780 nm to excite the autofluorescence signal from the scaffolds (NADH),
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split with a 568 nm dichroic mirror, and collected through a 525/50 nm bandpass filter. The signal was
collected over a 400 µm × 400 µm field of view at 2-µm z-step-size along the scaffold thickness.
2.5. Effect of Surface Modification on Cell Growth
hCB-ECs and HUVECs were seeded in NT and TC scaffolds at 10,000 cells/scaffold and cultured
for 7 days. The culture medium was changed every other day and cultures were maintained in a
humidified environment at 37 ◦C and 5% CO2. Cell growth was evaluated after 7 days of culture.
A sample of approximately 25 mm2 was cut from each scaffold, and cell number was measured by MTS
assay. Briefly, cell-seeded scaffolds were incubated in culture medium supplemented with CellTiter
96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) at 37 ◦C for 4 h.
Supernatant was collected and the absorbance at 490 nm was recorded. Background absorbance from
the NT and TC scaffolds was obtained from nonseeded scaffolds. Cell number was calculated based
on our calibration curves (Figure S3).
For cell imaging, the scaffolds were fixed with 2% formaldehyde and stained with Alexa Fluor®
568 phalloidin (Life Technologies, Carlsbad, CA, USA) to visualize f-actin following the manufacturer’s
instructions. To stain the nuclei, the scaffolds were treated for 24 h with VECTASHIELD® DAPI
mounting medium (Vector Laboratories, Burlingame, CA, USA). The Pitt AIM with a 20× water
immersion objective was used to visualize the cells growing in the scaffolds along the scaffold
depth. The nuclei (blue), fibers (green), and f-actin (red) were imaged simultaneously and colocalized
using three different photomultiplier tubes (PMTs). The laser was centered at λ = 780 nm to excite
simultaneously DAPI, the autofluorescence signal from the scaffolds (NADH), and Alexa Fluor® 568.
In the first PMT, the DAPI signal was split with a 505 nm dichroic mirror and collected through a
460/80 bandpass filter. In the second PMT, the signal from the scaffolds was split with a 568 nm
dichroic mirror and collected through a 525/50 bandpass filter. Alexa Fluor® 568 signal was acquired
in the third PMT by splitting the signal with a 568 nm dichroic mirror and collecting using a 607/70
bandpass filter. The colocalized image stacks from the cell nuclei, the fibers, and f-actin were merged
to visualize the cell location in the scaffolds. Maximum intensity projections (MIPs) were produced to
visualize the total number of cells in the field of view. The percentage of cell infiltration was calculated
as the ratio of the length that cells migrating through the flat sheet from the top to the bottom relative
to the flat sheet thickness. For instance, in a cell-seeded flat sheet, we obtained 20 images every 2 µm
in the Z-direction; the flat sheet had an estimated thickness of 40 µm. If the cells only appear in the
first five images, it means the cells migrated through the first 2 × 5 = 10 µm. Therefore, the percentage
of cell infiltration is calculated as 10/40 = 25% of that specific sample.
2.6. Platelet Activation and Platelet Adherence
De-identified human whole blood was obtained at the University of Arizona Sarver Heart Center
in accordance with IRB-approved protocols. Briefly, 30 mL of whole blood was drawn through
venipuncture into 3 mL of acid citrate dextrose A. Subsequently, the blood was centrifuged at 500× g
for 15 min to obtain platelet-rich plasma, which was gel-filtered through a column of Sepharose 2B
beads (GE Healthcare Life Sciences, Marlborough, MA, USA) with HEPES-modified Tyrode’s buffer
(Boston BioProducts Inc, Ashland, MA, USA), to collect erythrocyte-free platelets. With the aim of
quantifying the activation of platelets caused by the contact with cell-seeded scaffolds, the platelet
concentration was diluted to 20,000 platelets/µL in HEPES-modified Tyrode’s buffer, with 3 mM CaCl2
added 10 min prior to any experiment to avoid platelet-platelet activation.
Platelet activity state (PAS) was measured using a modified-prothrombinase assay reported in the
literature [42,43]. Briefly, after 7 days of hCB-EC and HUVEC culture in NT or TC scaffolds, a sample
of 20,000 platelets/µL was perfused onto the surface of the cell-seeded scaffolds and incubated at
37 ◦C for 0, 1, and 2 h. After incubation, 100 pM factor Xa, 5 mM calcium, and 200 nM acetylated
prothrombin, were added and incubated for 10 min. Thrombin generation was quantified through
spectrophotometric analysis over 7 min at an absorbance wavelength of 405 nm to obtain the PAS
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values, using Chromozym-TH (Roche, Penzberg, Germany) as the thrombin-specific chromogenic
peptide substrate. The platelets in a control tube were fully activated by sonication. Each PAS value
was normalized to the PAS value obtained in the control tube [43].
Samples were prepared for scanning electron microscopy (SEM) following Merkle et al., with
minor modifications [43]. Nonadherent platelets were gently washed away with 1× DPBS, and the
samples were immediately fixed with a solution composed of 2% formaldehyde and 2% glutaraldehyde
in 1× DPBS for 4 h. The samples were washed with 25% ethanol for 15 min and dehydrated in 50%,
75%, and 100% ethanol at 15-min intervals. The samples were treated with critical point drying in
CO2 using an E3100 Critical Point Dryer (Quorum Technologies LTDA, England). Each sample was
then mounted with carbon tape and coated with platinum for 30 s in a Hummer 6.2 argon gas sputter
system (Anatech LTD, Battle Creek, MI, USA). All samples were imaged using a field emission SEM
(Hitachi, Tokyo, Japan) with the working distance and accelerating voltage set to enhance the contrast
of adhered platelets against the cell surfaces. Platelet count on scaffolds was determined using ImageJ.
For each manual count, 10 random 40,000 µm2 sections of area were selected and averaged to estimate
the relative adherence of platelets on each scaffold treatment of each cell type [43,44]. Platelets were
characterized based on their characteristic size (2.3–4.3 µm) and shape [45]. Aggregated platelets were
excluded during platelet counting. Percentage of cell coverage was quantified by segmenting the
SEM images and dividing the pixels corresponding to the cell area by the total number of pixels in
the image.
2.7. Response to Interleukin 1 Beta (IL-1β) and Endothelial Nitric Oxide Synthase (eNOS) Production
To examine the response to IL-1β, after 4 days of hCB-EC and HUVEC culture in NT or TC
scaffolds, recombinant human IL-1β (Life Technologies, Carlsbad, CA, USA) was added to each
scaffold at a final concentration of 0.5 ng/mL. After 72-h treatment, the scaffolds with or without IL-1β
were fixed with 2% formaldehyde. To examine the eNOS production, a separate set of cultures of
hCB-EC and HUVEC in NT or TC scaffolds were fixed with 2% formaldehyde at day 7.
An in-cell enzyme-linked immunosorbent assay (ELISA) was performed using mouse
anti-intercellular adhesion molecule 1 (ICAM-1; Abcam, Cambridge, United Kingdom), mouse
anti-vascular cell adhesion molecule 1 (VCAM-1; Abcam), and mouse anti-eNOS primary antibodies
(Abcam). Primary antibodies were conjugated with HRP rabbit anti-mouse polyclonal secondary
antibodies (Abcam) and one-step ultra TMB ELISA (Thermo Fisher Scientific, Waltham, MA, USA) was
used to detect HRP activity following the manufacturer’s instructions. Absorbance was recorded at
450 nm in a Synergy H1 plate reader (BioTek, Winooski, VT, USA). Background absorbance from the NT
and TC scaffolds was obtained from non-seeded scaffolds. The ICAM-1, VCAM-1, and eNOS results
were normalized to the average cell number calculated from the MTS calibration curves (Figure S3).
Detailed information on the antibodies used is provided in Table S1.
2.8. Statistical Analysis
All values are presented as the mean ± standard deviation unless otherwise specified.
The statistical analysis was performed using the software package SPSS (IBM, Armonk, NY, USA).
For surface roughness, fiber diameter, scaffold thickness, scaffold porosity, cell proliferation, and ELISA
analyses, the statistical analysis was completed using two-way ANOVA with Tukey’s range tests to
compare between two cell types and two scaffolds. For nitric oxide synthase production, platelet
activity assay, and platelet adherence analyses, a one-way ANOVA was performed with a post hoc
analysis using individual two-sample two-tailed t-tests. The significant difference was determined
when the p-value < 0.05.
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3. Results
3.1. Cell Characterization
hCB-ECs were derived from the monocytes collected from cord blood. After differentiation, cells
were characterized using flow cytometry and immunocytochemistry. Figure 1 shows the results of
the flow cytometry represented in histograms. The blue histogram characterizes the signal obtained
from the cells treated with the antibodies and the gray histogram represents the cells that were not.
A shift in the histogram indicates a relative increase in the average cell fluorescence. Antibodies against
CD31 (Figure 1A) and CD105 (Figure 1B) were attached to the cell, confirming the expression of these
two endothelial cell-specific markers in our hCB-ECs. In contrast, the blue histogram for the cells
treated with the antibodies against CD45 (Figure 1C) did not shift, which can be interpreted as a lack of
CD45 expression in our hCB-ECs. These results confirm that hCB-ECs were successfully isolated and
there is no contamination from the hematopoietic lineage. Additionally, the immunocytochemistry
corroborated the expression of CD31 exclusively in the cell membrane at the cell–cell junctions
(Figure 1D).
Figure 1. Characterization of human cord blood-derived endothelial cells (hCB-EC) monolayers using
flow cytometry and immunocytochemistry. (A–C) Flow cytometry results show that hCB-ECs are
positive for endothelial cell markers CD31 and CD105 while negative for CD45, a hematopoietic marker.
(D) Immunocytochemistry of CD31 shows that the expression of CD31 is detected on the cell membrane
(green—CD31; blue—nuclei). Scale bar = 20 µm.
3.2. Scaffold Characterization
AFM was performed in order to study the effect of thermoforming on surface roughness, which
represents the average change in height on the surface with respect to a reference point. In this case,
the reference points are the glass coverslips which the individual samples were laid on prior to imaging.
No significant difference in roughness was found between the thermoformed and the nontreated
scaffolds (299.30 nm ± 27.53 nm vs. 331.53 nm ± 23.44 nm).
Figure 2 summarizes the effect of thermoforming and coating on scaffold microstructure. Figure 2A
shows representative SEM images of the nontreated (NT) and thermoformed/coated (TC) scaffolds.
The scaffold porosity and fiber diameter were calculated from these SEM images. The histogram of fiber
diameter shows a distribution of thinner fibers in the TC scaffolds (Figure 2B), which can be observed in
the TC SEM images. A significant reduction in porosity was found in the TC group (36.3% ± 2.39% vs.
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41.1%± 2.54%) (Figure 2C). No significant difference was detected between the thicker fibers of the TC
scaffolds and the fibers from NT scaffolds (0.42 µm± 0.1 µm vs. 0.40 µm± 0.12 µm). Scaffold thickness
was calculated using the Z stacks from the multiphoton images. A significant reduction in thickness was
found in the TC group (35.33 µm± 2.74 µm vs. 61.33 µm± 7.08 µm) (Figure 2D).
Figure 2. Effect of thermoforming and coating on polycaprolactone/gelatin/fibrinogen scaffolds.
(A) Representative SEM images of nontreated (NT) or thermoformed and coated (TC) scaffolds.
(B) Fiber diameter distribution in NT and TC scaffolds was calculated from the SEM images. NT
scaffolds have a normal fiber size distribution with fibers ranging from 0.1 to 0.74 µm. The TC scaffolds
have a bimodal fiber size distribution with thin fibers ranging from 0.02 to 0.12 µm, and thick fibers
ranging from 0.12 to 0.7 µm (n = 6 scaffolds, 120 fibers). (C) Average porosity results calculated from
the SEM images show a significant decrease in TC scaffolds (* p < 0.05; n = 6 scaffolds). (D) A significant
reduction in thickness calculated from multiphoton images was found in the TC group (* p < 0.05;
n = 6 scaffolds).
3.3. Effect of Surface Modification on Cell Attachment and Cell Growth
To evaluate the effect of thermoforming and coating on endothelial cell growth, cell number of
hCB-ECs and HUVECs in NT or TC scaffolds was evaluated at day 7 using MTS assays (n = 3 in each
group). A significant increase in cell number was observed for hCB-ECs compared to HUVECs in
NT (4.9 × 103 ± 432.04 vs. 3.04 × 103 ± 102.6, p = 0.003) and TC scaffolds (5.71 × 103 ± 286.7 vs.
3.40 × 103 ± 102.06, p = 0.001) (Figure 3).
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Figure 3. Cell number of hCB-ECs and human umbilical vein endothelial cells (HUVECs) cultured
in NT or TC scaffolds at day 7. The cell number was calculated from the MTS calibration curves.
A significant increase in hCB-ECs was found in NT and TC scaffolds when compared to HUVECs
(* p < 0.05, n = 3).
To evaluate cell attachment, the cells in scaffolds were stained with DAPI (nuclei) and Phalloidin
(F-actin) at day 7. Representative images of maximum intensity projections (MIPs) from each group
is presented in Figure 4. We found that the combined surface modification of thermoforming and
coating favor cell spreading and cell attachment compared to the NT scaffolds. When we calculated the
percentage of cell infiltration from the multiphoton z-stack images, no significant difference was found
between hCB-ECs cultured in TC and NT scaffolds (20.40% ± 4.5% vs. 17.2% ± 3.72%) or HUVECs
cultured in TC and NT scaffolds (27.01% ± 4.34% vs. 26.01% ± 1.81%). In addition, no significant
difference in infiltration was observed between hCB-ECs and HUVECs cultured in TC scaffolds
(20.40% ± 4.5% vs. 27.01% ± 4.34%) or NT scaffolds (17.2% ± 3.72% vs. 26.01% ± 1.81%). Interestingly,
we noticed that hCB-ECs have a lower cell infiltration than HUVECs in both NT and TC scaffolds.
Figure 4. Maximum intensity projection multiphoton images of hCB-ECs or HUVECs cultured in
nontreated (NT) or thermoformed/coated (TC) scaffolds after 7 days of culture (green—scaffolds;
blue—nuclei; red—F-actin). The combined surface modification of thermoforming and coating favor
cell spreading and cell attachment, especially for hCB-ECs. Scale bar = 100 µm.
3.4. Platelet Activation and Adhesion
The PAS was calculated for platelets on NT or TC scaffolds seeded with hCB-ECs or HUVECs
using a prothrombinase assay. A sample of diluted platelets was pipetted on top of the seeded scaffolds
and incubated for 0, 1, and 2 h. After incubation, factor Xa, Ca2+, and acetylated prothrombin were
added to the samples and the generation of thrombin as a measurement of platelet activation was
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quantified by spectrophotometry. PAS values were defined as the ratio of thrombin generated by the
samples to thrombin generated by sonication. In Figure 5, we found that in the TC samples, regardless
of the cell type, PAS values decrease after 1 h indicating a possible deactivation of platelets. On the
contrary, in the NT scaffolds, the PAS values increased over time suggesting a constant activation of
platelets. Comparisons were made between scaffolds within the same cell type and between cell types
within the same scaffold. A significant difference in absorbance for thrombin generation was found for
the NT and TC scaffolds seeded with hCB-ECs at 1 h (0.049 ± 0.003 vs. 0.026 ± 0.001, p = 0.0002) and
2 h (0.05 ± 0.003 vs. 0.0049 ± 0.002, p = 2.03 × 10−10) of platelet–prothrombinase incubation. Also,
when comparing the thrombin absorbance results for the NT and TC scaffolds seeded with HUVECs,
a significant difference in absorbance was found at 0 h (0.081 ± 0.01 vs. 0.024 ± 0.002, p = 0.001), 1 h
(0.12 ± 0.04 vs. 0.024 ± 0.001, p = 9.83 × 10−7), and 2 h (0.135 ± 0.03 vs. 0.019 ± 0.001, p = 4.3 × 10−10).
A significant decrease in thrombin generation was found in the NT scaffolds seeded with hCB-ECs
compared to the ones with HUVECs at 0 h (0.018 ± 0.001 vs. 0.081 ± 0.01, p = 0.001), 1 h (0.049 ± 0.003
vs. 0.024 ± 0.001, p = 5.46 × 10−7), and 2 h (0.05 ± 0.003 vs. 0.135 ± 0.002, p = 2.44 × 10−9). For the TC
scaffolds seeded with hCB-ECs, the thrombin generation by the perfused platelets was significantly
lower when compared to the TC scaffolds seeded with HUVECs after 2 h of incubation (0.0049 ± 0.002
vs. 0.019 ± 0.001, p = 4.3 × 10−10).
Figure 5. Platelet activity state (PAS) of hCB-EC or HUVEC seeded on thermoformed and coated
(TC) scaffolds compared to nontreated (NT) scaffolds at 0, 1, and 2 h. TC groups have lower platelet
activation when compared to NT groups; hCB-ECs have lower platelet activation than that of HUVECs
(comparisons between hCB-EC and HUVEC cultured in same scaffold and comparisons between NT
and TC of same cell type, * p < 0.05, n = 4).
Platelet adhesion is presented in Figure 6. Figure 6A shows representative SEM images taken for
each replicate of NT and TC scaffolds seeded with either hCB-ECs or HUVECs. Cells seeded on NT
scaffolds were not able to cover the entire surface, suggesting the presence of material fibers where
many platelets are deposited. On the contrary, in TC scaffolds the cells were able to cover almost the
entire surface of leaving almost no material fibers exposed reducing the adhesion of platelets. In NT
scaffolds, HUVECs have fewer cells attached to the surface than hCB-ECs, leaving more fibers exposed.
Similarly, in TC scaffolds HUVECs present more gaps in between the cells resulting in higher platelet
adhesion. Figure 6B shows the results of the platelet counts from the SEM images. A significant
reduction was found in the number of platelets adhered to both NT (186.9 ± 56.39 vs. 242.5 ± 39.22,
p = 0.025) and TC (55.4 ± 7.31 vs. 65.77 ± 5.51, p = 0.0033) scaffolds when hCB-ECs were seeded.
When assessing the differences between scaffold types, the TC had a significantly lower number of
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platelets deposited as compared to the nontreated with either hCB-ECs (55.4 ± 7.31 vs. 186.9 ± 56.39,
p = 0.000017) or HUVECs (65.77 ± 5.51 vs. 242.5 ± 39.22, p = 8.4 × 10−11). Figure 6C presents the
quantification of cell coverage calculated from the SEM images. A significant increase in cell coverage
was found for hCB-ECs growing in TC compared to NT surfaces (99.73% ± 0.053% vs. 66.72% ± 2.07%,
p = 0.00023). Similarly, HUVEC presented a significant increase in coverage of TC compared to NT
surfaces (99.08% ± 0.13% vs. 40.19% ± 5.83%, p = 0.0003). hCB-ECs show significantly more covered
area than HUVEC seeded in NT scaffolds (66.72% ± 2.07% vs. 40.19% ± 5.83%, p = 0.037).
Figure 6. Assessment of platelet adhesion of hCB-ECs or HUVECs cultured on thermoformed/coated
(TC) scaffolds compared to nontreated (NT) scaffolds. (A) Representative SEM images of each replicate
in each experimental group. White arrows are pointing at platelets. Scale bar = 50 µm. (B) Platelet
counts show that a significant reduction of platelet number in TC groups (* p < 0.05, n = 10). (C) Cell
coverage results show that thermoforming and coating increase the cell coverage of scaffolds, and that
hCB-ECs have higher cell coverage than HUVECs on NT scaffolds (* p < 0.05, n = 3).
3.5. Inflammatory Response and eNOS Production
To determine if the cells growing on TC scaffolds can produce eNOS in static conditions,
the expression of eNOS was quantified after 7 days in culture using in-cell ELISA. A baseline for
eNOS expression was established using NT scaffolds. The absorbance at 450 nm as a result of eNOS
production was normalized to the absorbance of MTS assay (490 nm) of hCB-ECs and HUVEC after
7 days growing in the TC and NT scaffolds. The eNOS production was found to be significantly lower
in hCB-ECs as compared to HUVECs (6.14 ± 1.04 vs. 11.61 ± 1.04; p = 0.024) when the cells are seeded
on NT scaffolds (Figure 7A). The production of eNOS by HUVECs growing in the TC scaffolds is
significantly lower as compared to their eNOS production when these cells are seeded in NT surfaces
(5.52 ± 0.48 vs. 11.61 ± 1.04; p = 0.006).
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To study the inflammatory response of hCB-ECs and HUVEC on the TC scaffolds, IL-1β was
added to the culture and the expression of ICAM-1 and VCAM-1 was quantified using in-cell ELISA.
For the hCB-ECs and HUVECs seeded onto TC scaffolds, the addition of IL-1β increased the absorbance
at 450 nm. An increase in absorbance is correlated with the expression of inflammation associated
proteins VCAM-1 and ICAM-1. All absorbance values were normalized by the MTS assay (490 nm) of
hCB-ECs and HUVEC after 7 days growing in the TC scaffolds. A significant decrease in VCAM-1
production was found comparing hCB-ECs to HUVECs after the addition of IL-1β (1.47 ± 0.17 vs.
2.34 ± 0.17; p = 0.00058) (Figure 7B). The expression of ICAM-1 is also significantly lower in hCB-EC
as compared to HUVEC seeded scaffolds without (0.65 ± 0.11 vs. 1.01 ± 0.089; p = 0.0015) and with
IL-1β stimulation (0.86 ± 0.07 vs. 1.56 ± 0.19; p = 0.00067) (Figure 7C).
Figure 7. Endothelial nitric oxide synthase (eNOS) production and response to IL-1β of hCB-EC- and
HUVEC-seeded scaffolds. (A) eNOS ELISA was quantified and normalized to MTS assay. The eNOS
production is significantly lower in hCB-ECs as compared to HUVECs when seeded on NT scaffolds
(* p < 0.05; n = 4). (B) Anti-vascular cell adhesion molecule 1 (VCAM-1) ELISA in TC scaffolds with or
without the addition of 0.5 ng/mL of IL-1β show that HUVECs have higher response compared to
hCB-ECs (* p < 0.05; n = 4). (C) ELISA of anti-intercellular adhesion molecule 1 (ICAM-1) shows that
HUVECs have higher response compared to hCB-ECs (* p < 0.05; n = 4).
4. Discussion
The purpose of this study was to evaluate the surface modification of a biomaterial to promote
endothelialization of electrospun scaffolds by thermoforming and coating with collagen IV and
fibronectin and to quantify the performance of cord blood endothelial cells on our biomaterial surface
and its potential for vascular tissue engineering applications.
Our research team was able to isolate mononuclear cells from human umbilical cord
blood, differentiate them into endothelial cells, and culture hCB-ECs on electrospun scaffolds
while maintaining endothelial cell phenotype. Our findings suggest that scaffolds composed of
polycaprolactone/gelatin/fibrinogen that have been surface modified by thermoforming and coating
with a mixture 1:1 collagen IV to fibronectin will promote the formation of an endothelial monolayer.
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In these scaffolds cell growth is encouraged, resulting in a monolayer of endothelial cells. hCB-ECs
proliferate more robustly on our surface modified scaffolds than HUVECs, and the maintenance of
the endothelial cell function of both hCB-ECs and HUVECs is comparable. hCB-EC-seeded scaffolds
upregulated the adhesion molecules ICAM-1 and VCAM-1 when stimulated with the pro-inflammatory
cytokine IL-1β. Our hCB-ECs also displayed the ability to produce the vasoregulatory- and
hemocompatibility-related enzyme eNOS and reduce platelet adhesion and activation.
Our source of endothelial cells is cord blood, which is characterized by a unique richness in
highly proliferative stem and progenitor cells [46]. Cord blood is readily available, can be collected
noninvasively without risk to the mother or infant donor, and can be tested and preserved for long
periods of time for future use [47]. This source of endothelial cells has many advantages compared
to bone marrow and peripheral blood. Some of the main advantages are the proliferative capacity
of the cord blood progenitor cells, higher number of stem cells per volume of blood, and a higher
tolerance of cord blood progenitor cells of human leukocyte antigen mismatches [48]. Moreover,
hCB-ECs can be used in the treatment of acute ischemic disease, in aging patients, and patients
with risk of cardiovascular disease, as opposed to peripheral blood derived endothelial cells [48].
The endothelial cells from cord blood will be treated as a nonautologous source of cells that has to
be donor matched [31,49]. Generally, it has been accepted that human leukocyte antigen mismatches
are better tolerated with cells derived from cord blood as oppose to bone marrow, resulting in less
graft versus host disease [48]. This suggests that endothelial cells derived from cord blood are more
adaptable as they are young and not fully differentiated in early passages, therefore they are suitable
for clinical applications.
Different efforts have been made for the endothelialization of small diameter vascular grafts,
and many of them have used surface modified scaffolds fabricated with synthetic polymers which
have excellent biomechanical properties but low biocompatibility [5,50–58]. Surface modifications
can reduce hydrophobicity of the material and therefore increase biocompatibility. One of the most
popular techniques for improving biocompatibility and endothelial cell adhesion is immobilization
of peptide ligands onto the grafts. Peptide sequences such as RGD, GRGDSP, and DGEA have been
utilized since they interact directly with endothelial cell receptors and increase cell attachment [59].
In this work, we demonstrated that a scaffold made of a blend of synthetic and natural polymers
including polycaprolactone, gelatin, and fibrinogen following by thermoforming and coating with a
mixture of collagen IV and fibronectin improves hCB-EC cell growth. This unique hybrid biomaterial
possesses the RGD peptide from gelatin [60,61], fibrinogen [62], and fibronectin [63]; GRGDSP peptide
from fibronectin [64]; DGEA peptide from gelatin [65]; and FYFDLR from collagen IV [66]. All these
are important peptides recognized by integrins in the endothelial cell membrane [66–69]. Furthermore,
the inclusion of polycaprolactone to the polymeric blend reduced fiber diameter which appears to
promote cell attachment [70] and endothelial cell proliferation [71]. The thermoforming process aimed
to smooth the surface of electrospun scaffolds. Surprisingly, thermoforming did not significantly alter
the surface roughness in this study. However, the combined surface modification of thermoforming
and coating decreased both scaffold porosity and scaffold thickness and altered the distribution of fiber
diameters with the appearance of small fibers branching out from the major fibers. We observed better
cell attachment in the thermoformed and coated scaffolds demonstrating that the surface-modified
scaffolds favor the development of an endothelial cell monolayer. We noticed a difference between
the cell number reported for the NT group in Figure 3 and that observed in Figure 4. We speculate
this may be due to the staining and intensive washing required prior to multiphoton imaging but not
required for an MTS assay, which may remove cells not strongly attached to the nontreated scaffolds.
Further experiments should be run to confirm if the decreased strength of attachment of cells placed
on NT materials is responsible for the lower cells present in Figure 4. Should this be the case, choosing
the TC group would be advantageous given the increased levels of shear stress expected in vivo.
It is possible that the pressure applied to the scaffolds by thermoforming may lead to the
production of a more compact fiber arrangement that aids with the retention of coating proteins
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and that the appearance of small fibers may be due to the coating process creating more contact points
for the cells. Thus, the combined surface modification of thermoforming and coating facilitated better
hCB-EC attachment and cell growth. Future work will be beneficial to understand the mechanisms by
which this process is governed.
Our goal is not only to promote cell attachment and cell growth of hCB-ECs in our electrospun
scaffolds but also to assess whether the attached cells can function as mature endothelial monolayers.
For this purpose, we evaluated three important characteristics of a healthy endothelial cell layer under
static conditions: the response to a pro-inflammatory stimulus, the production of eNOS (enzyme
directly related with nitric oxide generation), and the antithrombotic capacity. We investigated the
inflammatory response by exposing the hCB-EC- and HUVEC-seeded scaffolds to a pro-inflammatory
cytokine IL-1β by assessing the production of VCAM-1 and ICAM-1. Our results show that in both cell
types VCAM-1 and ICAM-1 were upregulated, demonstrating a positive response to IL-1β as occurring
in the healthy vasculature [72–75]. Interestingly, hCB-ECs intrinsically have a lower production of the
VCAM-1 and ICAM-1 which correlates to reduced recruitment of leucocytes/macrophages and thus a
reduced probability of graft intimal hyperplasia and atherosclerosis in vivo [76,77].
In endothelial cells, eNOS is responsible for endothelium-derived nitric oxide (NO) production.
In this study we measured eNOS production of hCB-ECs or HUVECs seeded on thermoformed/coated
scaffolds and compared this with that of cells seeded on nontreated scaffolds. Both cell types expressed
eNOS in static conditions in both the thermoformed/coated and nontreated scaffolds indicating
that their endothelial cell phenotype is preserved. eNOS production in hCB-ECs is lower than the
amount produced by HUVECs in both growing surfaces. These results are similar to those reported
by Brown et al. (2009) who showed that hCB-ECs produced a significantly lower amount of eNOS
than aortic ECs in static conditions [30]. Similarly, in the work of Yuan et al. (2016), the authors
found that endothelial progenitor cells have a markedly lower expression of eNOS as well as activity
levels compare to HUVECs and aortic ECs. They concluded that the expression of low levels of
eNOS in endothelial progenitor cells compared to mature endothelial cells is due to their higher
extracellular matrix deposition [78]. In our work, we also observed that eNOS is reduced significantly
for HUVECs growing on TC scaffolds compared to NT scaffolds. This may due to the use of fibronectin
in our coating causing the partial downregulation of eNOS in HUVECs which is in line with the
study by Viji et al. (2009), who found that HUVECs growing on fibronectin-coated glass slides at a
concentration of 50 µm/mL have a significantly reduced eNOS activity when compared to noncoated
glass slides [79]. Yuan et al. also found that HUVEC growing in fibronectin-coated flasks have a
significant reduction in eNOS mRNA and protein levels compared to HUVEC cultured on polystyrene
flasks [78]. In vivo, the predominant physiological stimulus for eNOS active phosphorylation and
subsequent NO segregation is wall shear stress [80–82]. It has been demonstrated that eNOS is
produced in fewer quantities in endothelial cells cultured in static conditions [80,83,84]. In our work,
no significant difference was found between the eNOS protein levels of hCB-ECs growing in NT and
TC scaffolds, but it is possible that eNOS production may increase in hCB-EC-seeded scaffolds under
flow conditions [30,85].
We also assessed antithrombotic capacity by evaluating platelet activation and deposition when in
contact with either nontreated or thermoformed/coated scaffolds preseeded with hCB-ECs or HUVECs.
Figure 5 shows the results of the platelet activity state (PAS) assay where the PAS values represent
the amount of acetylated thrombin formed by the platelets in contact with the studied samples [43].
Overall, the PAS values over the course of 2 h are lower for the TC scaffolds showing a deactivation
after the first hour. It is known that platelets are deactivated by molecules secreted by the endothelium
such as NO, prostacyclin, and prostaglandin D [86], and that under normal conditions the coagulation
cascade is self-regulated. Furthermore, molecules secreted by platelets and involved in further platelet
activation, such as platelet activating factor, thrombin, and tumor necrosis factor-α (TNF-α), trigger
the production of NO by the endothelial monolayer resulting in a negative feedback system which
deactivates platelets [87–89]. The PAS results correlated with the number of platelets deposited in the
J. Clin. Med. 2019, 8, 185 15 of 21
scaffolds. There is a significantly lower number of platelets adhered to cell seeded TC scaffolds because
of the development of a confluent monolayer. Even though HUVECs formed a monolayer on the TC
samples, there were some material fibers exposed for this group likely promoted platelet adhesion. In
the nontreated scaffolds, the cells did not cover the entire scaffold, leading to large areas where the
material fibers were exposed and the rapid deposition of platelets. According to our findings, there
is an inverse relationship between endothelial cell coverage and platelet deposition on the surface.
The platelet counts are higher in the scaffolds where the cells are not confluent, and the material is
uncovered. Previous studies have shown that endothelial progenitor cells such and hCB-ECs are able
to inhibit the attachment and activation of platelets in vitro [90,91]. Moreover, our results are also
similar to the study by Brown et al. (2010) who demonstrated that hCB-ECs have superior adhesion
and proliferation to vessel-derived cells such as human aortic endothelial cells, and as such, were
able to reduce the platelet adhesion and prevent thrombosis in a vein graft [47]. Future studies in our
laboratory will utilize immunocytochemistry to further quantify the expression of activated platelet
specific markers (e.g., CD62) as well as investigate the effects of shear induced platelet activation using
a physiologically realistic pulsatile flow experimental setup.
It should be noted that we did not quantify any of our outcomes on electrospun constructs
thermoformed and treated with collagen IV or fibronectin individually. The choice of studying our
outcomes on thermoformed and electrospun constructs simultaneously coated with both collagen
IV and fibronectin was made after observing the data in Figure S1, which demonstrates that
this coating had the highest trend of cell count on coverslips. Therefore, a limitation of our
study is that we do not know if the individual coating of collagen IV or fibronectin following
thermoforming would have resulted in similar, better, or worse coverage as seen in Figure S2. Another
limitation of our study is that all cell experiments were completed under static conditions. Although
in vitro endothelialization studies of electrospun scaffolds are primarily performed under static
conditions [44,92–94], we recognize the importance of evaluating endothelial cell function under
physiological shear stress, an important mechanical stimulus controlling cell response [95].
For example, one of the most important functions of endothelial cells in the vasculature is the
production of NO, a potent vasodilator and anti-inflammatory mediator [96]. It is reported that shear
stress stimulates eNOS production, eNOS phosphorylation, and NO synthesis [97–101]. Therefore,
to be able to make further conclusions about the preservation of endothelial cell phenotype of hCB-EC
seeded in thermoformed and coated scaffolds, future studies will focus on elucidating growth and
functionality under physiological shear stress. Another limitation of our study is that all scaffolds
reported were flat sheets and not tubular scaffolds. One of our ongoing studies is to assess hCB-EC
cell growth and function in tubular scaffolds, both in static and flow conditions. Future pulsatile flow
experiments will be performed in a parallel plate flow chamber for planar scaffolds and in custom
tubular bioreactors.
5. Conclusions
hCB-ECs cultured on scaffolds composed of polycaprolactone, gelatin, and fibrinogen that are
thermoformed and coated with collagen IV and fibronectin are attractive for endothelial cell attachment
and cell growth. These cells have the capability to proliferate and form a stable monolayer on the
surface of the planar scaffold. Upon monolayer formation, hCB-ECs can produce eNOS, respond to the
addition of IL-1β through the upregulation of VCAM-1 and ICAM-1, and reduce platelet deposition
and activation rate. Our hCB-ECs have superior cell proliferation but lower inflammatory response
when compared to HUVECs in electrospun scaffolds.
The long-term goal of our team is to generate a TEVG that supports endothelial cell growth,
is biomechanically matched to a target artery, and remains functional and durable post-implantation
for artery replacement. With the present work, we demonstrate that thermoforming and coating on
polycaprolactone/gelatin/fibrinogen scaffolds enhances hCB-EC growth and improves maintenance of
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their EC phenotype in vitro. Future directions will include the development and assessment of layered
scaffolds as well as in vivo studies using an aortic implantation to functionally assess our TEVG.
We believe this work provides important findings towards the endothelialization of electrospun
scaffolds, and thus will have an impact on the field of tissue engineering and regenerative medicine.
We demonstrated that hybrid electrospun scaffolds that were surface modified by the combined
treatments of thermoforming and coating and were subsequently seeded with endothelial cells derived
from cord blood show promise for vascular tissue engineering.
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ColI and ColIV (ColI/ColIV), ColI and Fib (ColI/Fib), or ColIV and Fib (ColIV/Fib) in 96-well plates, Figure S2.
Maximum intensity projection multiphoton images of hCB-ECs or HUVECs cultured in nontreated, thermoformed,
coated, or thermoformed coated scaffolds with collagen IV and fibronectin after 7 days of culture (green—scaffolds;
blue—nuclei; red—F-actin), Figure S3. MTS assay calibration curves for hCB-ECs and HUVEC (n = 6).
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